AstraZeneca’s FARXIGA® gets designation for Chronic Kidney Disease
AstraZeneca’s FARXIGA® was granted Breakthrough Therapy Designation (BTD) in the U.S. for Chronic Kidney Disease, following the DAPA-CKD Phase III
Read moreAstraZeneca’s FARXIGA® was granted Breakthrough Therapy Designation (BTD) in the U.S. for Chronic Kidney Disease, following the DAPA-CKD Phase III
Read moreAbbott declared the first patient has been enrolled in the DISTINCT study (Dorsal spInal cord STImulatioN vs mediCal management for
Read moreJanssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read moreIrish biotechnology firm Inflazome announced today that it has closed a share purchase agreement with Swiss pharma giant Roche in
Read moreSwiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read morePhase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read moreNestlé’s nutritional science brand Nestlé Health Science (NHSc) furthers efforts of food allergy prevention through the acquisition of California-based biopharmaceutical
Read moreBiotechnology has spearheaded the healthcare industry in investment action from private equity and venture capital during the first half of
Read moreEli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read moreSanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read more